EP 0436634 A1 19910717 - HIV PROTEINS AND PEPTIDES USEFUL IN THE DIAGNOSIS, PROPHYLAXIS OR THERAPY OF AIDS.
Title (en)
HIV PROTEINS AND PEPTIDES USEFUL IN THE DIAGNOSIS, PROPHYLAXIS OR THERAPY OF AIDS.
Title (de)
HIV-PROTEINE UND PEPTIDE UND DEREN VERWENDUNG ZUR DIAGNOSE, PROPHYLAXE UND THERAPIE VON AIDS.
Title (fr)
PROTEINES ET PEPTIDES DU VIH UTILES POUR LE DIAGNOSTIC, LA PROPHYLAXIE OU LA THERAPIE DU SIDA.
Publication
Application
Priority
- US 25294988 A 19881003
- US 35954389 A 19890601
- US 40766389 A 19890919
Abstract (en)
[origin: WO9003984A1] The subject invention concerns the identification of a portion of the HIV envelope protein called the principal neutralizing domain. Polypeptides comprising this domain have the capability of raising, and/or binding with, neutralizing antibodies. The invention further concerns novel HIV polypeptides which can be used in the diagnosis, prophylaxis, or therapy of AIDS. These polypeptides can be prepared by known chemical synthetic procedures, or by recombinant DNA means. The polypeptides pertain to the gp 120 subunit, amino acids 298-320, including the sequence .......gly-pro-gly...... and variants thereof. Multiepitope polypeptides comprising analogues of this peptide epitope from different HIV variants are referred to.
Abstract (fr)
L'invention concerne l'identification d'une partie de la protéine d'enveloppe du VIH appelée domaine de neutralisation principal. Des polypeptides comprenant ce domaine ont la capacité de développer des anticorps neutralisants et/ou de se lier à ceux-ci. L'invention concerne également de nouveaux polypeptides du VIH utilisables dans le diagnostic, la prophylaxie ou la thérapie du SIDA. On peut préparer ces polypeptides selon des techniques synthétiques chimiques connues, ou au moyen d'ADN de recombinaison. Ces polypeptides appartiennent à la sous-unité gp 120, amino acides 298-320, comprenant la séquence ......gly-pro-gly...... et des variantes de celle-ci. L'invention concerne en outre des polypeptides multiépitopes comprenant des analogues de cet épitope peptidique provenant de différentes variantes du VIH.
IPC 1-7
A61K 39/21; C07K 7/10; C12N 15/48; C12P 21/02; C12P 21/08; G01N 33/569
IPC 8 full level
A61K 38/00 (2006.01); A61K 39/21 (2006.01); A61K 39/395 (2006.01); A61K 39/42 (2006.01); A61K 49/00 (2006.01); C07K 5/10 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/16 (2006.01); C07K 16/00 (2006.01); C07K 19/00 (2006.01); C12N 15/09 (2006.01); C12P 21/02 (2006.01); C12P 21/08 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01); C12R 1/19 (2006.01)
CPC (source: EP KR)
C07K 14/00 (2013.01 - KR); C07K 14/005 (2013.01 - EP); G01N 33/56988 (2013.01 - EP); G01N 33/6878 (2013.01 - EP); A61K 38/00 (2013.01 - EP); A61K 39/00 (2013.01 - EP KR); C12N 2740/16122 (2013.01 - EP)
Designated contracting state (EPC)
AT BE CH DE FR GB IT LI LU NL SE
DOCDB simple family (publication)
WO 9003984 A1 19900419; AU 4403689 A 19900501; AU 640619 B2 19930902; DK 57391 A 19910529; DK 57391 D0 19910402; EP 0436634 A1 19910717; FI 911574 A0 19910402; IL 91843 A0 19900610; JP H04502760 A 19920521; KR 900701836 A 19901204; NZ 230855 A 19941026; PT 91881 A 19900430
DOCDB simple family (application)
US 8904302 W 19890929; AU 4403689 A 19890929; DK 57391 A 19910402; EP 89911309 A 19890929; FI 911574 A 19910402; IL 9184389 A 19890929; JP 51056789 A 19890929; KR 900701182 A 19900604; NZ 23085589 A 19891002; PT 9188189 A 19891003